Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
NAGE 
Niagen Bioscience, Inc. (NAGE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/18/2025: NAGE (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $11.4
1 Year Target Price $11.4
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 102.65% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 836.53M USD | Price to earnings Ratio 59 | 1Y Target Price 11.4 |
Price to earnings Ratio 59 | 1Y Target Price 11.4 | ||
Volume (30-day avg) 4 | Beta 1.95 | 52 Weeks Range 5.16 - 14.69 | Updated Date 08/18/2025 |
52 Weeks Range 5.16 - 14.69 | Updated Date 08/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.18 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 13.07% | Operating Margin (TTM) 15.66% |
Management Effectiveness
Return on Assets (TTM) 12.21% | Return on Equity (TTM) 33.47% |
Valuation
Trailing PE 59 | Forward PE 65.36 | Enterprise Value 743633586 | Price to Sales(TTM) 7.75 |
Enterprise Value 743633586 | Price to Sales(TTM) 7.75 | ||
Enterprise Value to Revenue 6.89 | Enterprise Value to EBITDA 50.62 | Shares Outstanding 78769696 | Shares Floating 51792712 |
Shares Outstanding 78769696 | Shares Floating 51792712 | ||
Percent Insiders 34.44 | Percent Institutions 30.6 |
Upturn AI SWOT
Niagen Bioscience, Inc.
Company Overview
History and Background
Niagen Bioscience, Inc. (also known as ChromaDex) was founded in 1999. It has evolved from a provider of reference standards and research chemicals to a life sciences company focused on NAD+ metabolism and aging. A significant milestone was the development and commercialization of Niagenu00ae, their patented form of nicotinamide riboside (NR).
Core Business Areas
- Nutraceuticals and Supplements: Development, marketing, and sale of dietary supplements, primarily focused on Nicotinamide Riboside (NR) under the brand name Tru Niagenu00ae. This segment targets consumers seeking to improve cellular energy and support healthy aging.
- Research and Development: Conducting scientific research and clinical studies to understand and validate the benefits of NR and other NAD+ precursors for various health conditions and aging. This also includes licensing intellectual property.
- Reference Standards and Chemicals: Providing high-purity analytical standards for pharmaceutical, chemical, and biotechnology industries to support quality control and research.
Leadership and Structure
ChromaDex is led by a management team with expertise in scientific research, business development, and consumer products. The company operates with a focus on scientific integrity and commercialization of its proprietary NR technology.
Top Products and Market Share
Key Offerings
- Product Name 1: Tru Niagenu00ae (Nicotinamide Riboside): A patented dietary supplement designed to boost NAD+ levels in the body, supporting cellular energy production and repair. Market share is difficult to precisely quantify in the broader supplement market, but it is a leading brand in the NR segment. Competitors include other NR-based supplements from companies like Elysium Health and other generic NR manufacturers. Revenue from Tru Niagenu00ae is the primary driver of ChromaDex's revenue.
- Product Name 2: Nicotinamide Riboside (NR) Reference Standards: High-purity NR for use in research and analytical testing. This is a niche market for scientific institutions and pharmaceutical companies. Competitors include other chemical suppliers and custom synthesis providers.
Market Dynamics
Industry Overview
ChromaDex operates in the rapidly growing dietary supplement and life sciences industries. The NAD+ precursor market, specifically NR, is a burgeoning segment driven by increasing consumer interest in anti-aging, cellular health, and energy metabolism.
Positioning
ChromaDex is positioned as a leader in the NR market due to its patented Niagenu00ae ingredient and robust scientific backing. Their competitive advantage lies in their proprietary technology, extensive patent portfolio, and ongoing clinical research.
Total Addressable Market (TAM)
The global dietary supplement market is valued at over $150 billion and is projected to grow. The specific market for NAD+ precursors is a significant and expanding subset of this. ChromaDex aims to capture a substantial portion of the NR market share within this larger TAM.
Upturn SWOT Analysis
Strengths
- Proprietary patented Niagenu00ae (NR) ingredient.
- Strong scientific evidence and clinical research supporting NR's benefits.
- Established brand recognition for Tru Niagenu00ae.
- Growing consumer awareness of NAD+ and its importance.
- Experienced leadership team.
Weaknesses
- Reliance on a single primary active ingredient (NR).
- High cost of production and potentially higher retail price compared to some competitors.
- Ongoing patent litigation and challenges.
- Dependence on third-party manufacturers for production.
- Limited diversification beyond the NR supplement market.
Opportunities
- Expansion into new geographic markets.
- Development of new product formulations and delivery methods for NR.
- Partnerships with pharmaceutical companies for therapeutic applications of NR.
- Increased global demand for anti-aging and wellness products.
- Potential for licensing NR technology to other industries.
Threats
- Intensifying competition from other NR suppliers and alternative NAD+ precursors.
- Regulatory changes impacting the dietary supplement industry.
- Adverse scientific findings or negative publicity regarding NR.
- Economic downturns impacting consumer discretionary spending on supplements.
- Patent expirations or successful challenges to existing patents.
Competitors and Market Share
Key Competitors
- Elysium Health Inc. (Privately Held)
- Life Extension (Privately Held)
- Jarrow Formulas (Privately Held)
Competitive Landscape
ChromaDex's advantage lies in its patented NR and scientific validation. However, competitors with similar or alternative NAD+ precursors, and those with lower price points, pose significant challenges. ChromaDex needs to continuously innovate and defend its intellectual property.
Growth Trajectory and Initiatives
Historical Growth: ChromaDex has demonstrated consistent revenue growth over the past several years, largely propelled by the increasing popularity and distribution of Tru Niagenu00ae.
Future Projections: Analyst estimates generally project continued revenue growth driven by market expansion and product penetration. Profitability projections depend on the company's ability to manage operational costs and navigate legal challenges.
Recent Initiatives: Key initiatives include expanding global distribution channels for Tru Niagenu00ae, investing in further clinical research, and strengthening the company's intellectual property portfolio.
Summary
ChromaDex (Niagen Bioscience, Inc.) is a leading innovator in the NAD+ precursor market, with its flagship product Tru Niagenu00ae driving significant revenue growth. The company's strengths lie in its patented technology and strong scientific foundation. However, it faces challenges related to competition, ongoing legal battles, and the need to achieve consistent profitability. Continued investment in R&D and strategic market expansion are crucial for its future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Financial Reports (e.g., 10-K, 10-Q)
- Industry Market Research Reports
- Financial News and Analysis Websites
- Company Press Releases
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. Data accuracy may vary, and external factors can significantly impact company performance. Investors should conduct their own due diligence before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Niagen Bioscience, Inc.
Exchange NASDAQ | Headquaters Los Angeles, CA, United States | ||
IPO Launch date 2008-07-15 | CEO & Director Mr. Robert N. Fried | ||
Sector Healthcare | Industry Biotechnology | Full time employees 104 | Website https://www.niagenbioscience.com |
Full time employees 104 | Website https://www.niagenbioscience.com | ||
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceuticalgrade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also offers the supply of phytochemical reference standards and other research and development services. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.